Ireland - English - HPRA (Health Products Regulatory Authority)

vetpharma animal health, s.l. - enrofloxacin - oral solution - 100 mg/ml - enrofloxacin - fowl - chicken, fowl - turkey - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

vetpharma animal health, s.l. - enrofloxacin - solution for injection - 100 mg/ml - enrofloxacin - bovine, porcine - antibacterial

United Kingdom - English - VMD (Veterinary Medicines Directorate)

vetpharma animal health, s.l - enrofloxacin - solution for injection - antimicrobial - cattle, pigs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

vetpharma animal health, s.l - enrofloxacin -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flunisolide 25ug - nasal spray solution - 25 mcg/dose - active: flunisolide 25ug

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - flunisolide 0.025% - nasal spray solution - 0.02 % - active: flunisolide 0.025%

United States - English - NLM (National Library of Medicine)

dispensing solutions inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 5 mg - singulair is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. singulair is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older). hypersensitivity to any component of this product.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 5 mg - montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. - hypersensitivity to any component of this product. pregnancy category b:  there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, montelukast sodium should be used during pregnancy only if clearly needed. teratogenic effect: no teratogenicity was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on aucs [see nonclinical toxicology (13.2)] . during worl

Philippines - English - FDA (Food And Drug Administration)

aldril pharmaceuticals, inc.; distributor: solvang pharmaceuticals, inc. - multivitamins , minerals - film-coated tablet - [see reverse]

Philippines - English - FDA (Food And Drug Administration)

solvang pharmaceuticals, inc - multivitamins , minerals - film-coated tablet - [see reverse]